ACE2 Expression in Pancreas May Cause Pancreatic Damage After SARS-CoV-2 Infection.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus that causes coronavirus disease 2019 (COVID-19) in human beings, has caused a serious public health issue.1 Attention to pancreatic injury is lacking, which may impact patients' prognosis. In this study, we explored the expression and distribution of angiotensin-converting enzyme 2 (ACE2), the receptor of SARS-CoV-2, in the pancreas. Combined with clinical data, we showed that pancreatic injury can occur in some COVID-19 patients.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus that causes coronavirus disease 2019 (COVID-19) in human beings, has caused a serious public health issue. Attention to pancreatic injury is lacking, which may impact patients’ prognosis. In this study, we explored the expression and distribution of angiotensin-converting enzyme 2 (ACE2), the receptor of SARS-CoV-2, in the pancreas. Combined with clinical data, we showed that pancreatic injury can occur in some COVID-19 patients.

Methods

A public database was used to explore the expression and distribution of ACE2 in normal pancreases. We also retrospectively analyzed patients diagnosed with COVID-19 from January 1, 2020, to February 15, 2020, in Wuhan Tongji Hospital and Wuhan Jin Yin-tan Hospital. We collected hospital admission data, laboratory tests, and imaging tests from clinical electronic medical records. Severe COVID-19 was defined when patients had 1 of the following criteria: (1) shortness of breath and respiratory frequency ≥30/min; (2) finger pulse oximeter oxygen saturation at rest of 93% or less; or (3) oxygenation index of 300 mm Hg or less. More details about clinical data and public data set analysis are described in the Supplementary Methods.

Results

In the GTEx database (https://gtexportal.org), we found that the messenger RNA level of ACE2 was higher in the pancreas than in the lung (Figure 1 A) (P < .001, Wilcoxon signed-rank test). To investigate the distribution of ACE2 in the pancreas, we analyzed 2 single-cell RNA sequencing data sets. After identifying different types of pancreatic cells (Figure 1 B and D), we found that ACE2 was expressed in both the exocrine glands and islets (Figure 1 C and E). The details are listed in Supplementary Table 1.

Figure 1

The expression and distribution of ACE2 in pancreas. (A) The messenger RNA level of ACE2 in multiple organs from GTEx samples. (B and D) The visualization of pancreatic cell distribution in GSE85241 and GSE84133. (C and E) The expression of ACE2 in different pancreatic cell in GSE85241 and GSE84133. ∗∗∗P < .001. UMAP, uniform manifold approximation and projection.

Supplementary Table 1

The Distribution of ACE2 in Several Types of Pancreatic Cells in 2 Single-Cell RNA Sequencing Data Sets

	GSE85241 (N = 55)	GSE84133 (N = 19)
Exocrine gland
Duct cell	14 (25.45%)	10 (52.6%)
Acinar cell	31 (56.36%)	1 (5.26%)
Endothelial cell	1 (1.82%)	0
Pancreatic islet
α cell	4 (7.27%)	0
β cell	4 (7.27%)	4 (21.05%)
PP and delta cell	1 (1.82%)	3 (15.79%)

NOTE. Individual differences between donors from different sources may lead to differences in the results from the 2 single-cell RNA sequencing data sets.

ACE2, angiotensin-converting enzyme 2; PP, pancreatic polypeptide.

Furthermore, we analyzed pancreatic injury after SARS-CoV-2 infection. Our study cohort included 121 COVID-19 patients (46 women, 75 men), with a median age of 57 years (interquartile range, 43–72 y). In mild cases, 1.85% (1 of 54) had increased levels of both amylase and lipase. In patients with severe COVID-19, 17.91% (12 of 64) and 16.41% (11 of 64) had increased amylase and lipase levels, respectively (Table 1 ). On computed tomography scan, 5 patients with severe COVID-19 (7.46%) showed changes in the pancreas, mainly focal enlargement of the pancreas or dilatation of the pancreatic duct, without acute necrosis. Of the 13 patients with pancreatic injury, 3 severe patients showed increased amylase and lipase levels on admission. In addition, 2 patients had a history of nonsteroidal anti-inflammatory drug use, and 4 patients had been treated with glucocorticoids during hospitalization, which may be associated with drug-induced pancreatitis (Supplementary Table 2). Three patients had suspected symptoms of pancreatitis such as abdominal pain or vomiting. Of note, the clinical symptoms could not be recorded among severe patients requiring mechanical ventilation under sedation. Meanwhile, 5 critically ill patients with pancreatic injury died and 8 were discharged. These clinical data show that pancreatic injury can occur in some COVID-19 patients, mainly in those with severe illness.

Table 1

Summary of the Study Patients

Characteristics	All patients (n = 121)	Nonsevere (n = 54)	Severe (n = 67)
Age, y (range, IQR)	57 (range, 18–87; IQR, 43–72)	53 (range, 18–83; IQR, 39–67)	62 (range, 24–87; IQR, 51–73)
Sex, n (%)
Female	46 (38.02%)	21 (38.89%)	25 (37.31%)
Male	75 (61.98%)	33 (61.11%)	42 (62.69%)
AMS/LPS increased, n (%)	13 (10.74%)	1 (1.85%)	12 (17.91%)
AMS increased	13 (10.74%)	1 (1.85%)	12 (17.91%)
LPS increased	12 (9.92%)	1 (1.85%)	11 (16.41%)
Imaging alteration, N∗ (%)
Normal	8 (3.62%)	1 (1.85%)	7 (10.44%)
Enlargement or dilation	5 (4.13%)	0	5 (7.46%)
Necrosis	0	0	0

NOTE. Data are shown as the median (range, IQR), n (%), or N∗ (%), where N is the number of patients with increased amylase and lipase levels.

AMS, amylase; IQR, interquartile range; LPS, lipase.

Supplementary Table 2

Clinical Characteristics of COVID-19 Patients With Pancreatic Injury

Variable, n (%) or median (IQR)	Normal range	Nonsevere (n = 1)	Severe (n = 12)
Age, y	–	44	62 (53–69)
Male	–	N	6 (50.0%)
BMI	20–25	28.4	27.2 (24.5–28.7)
Incubation period, d	2–7	4	4 (3–7)
Comorbidities
Hypertension	–	N	5 (41.7%)
Diabetes	–	Y	5 (41.7%)
CHD	–	N	1 (8.3%)
Presenting symptoms
Fever	–	Y	7 (58.3%)
Short of breath	–	N	8 (66.7%)
Cough	–	N	4 (33.3%)
Fatigue	–	N	4 (33.3%)
Diarrhea	–	N	2 (16.7%)
Headache	–	N	2 (16.7%)
Complications
ARDS	–	N	6 (50.0%)
Cardiac injury	–	N	2 (16.7%)
Kidney injury	–	N	4 (33.3%)
Liver injury	–	Y	7 (58.3%)
Shock	–	N	4 (33.3%)
NSAIDs used	–	N	2 (16.7%)
Laboratory findings on admission
WBC, ×109/L	3.5–9.5	5.62	4.56 (3.80–10.20)
Lymphocyte count, ×109/L	1.10–3.20	0.89	0.66 (0.43–0.92)
Neutrophil count , ×109/L	1.80–6.30	4.13	5.02 (2.27–7.20)
Platelet count, ×109/L	125.0–350.0	227	156 (145–280)
Hemoglobin, g/L	130–175	127	125 (121–150)
ALT, U/L	7.0–40.0	45	31 (20–78)
AST, U/L	13.0–35.0	37	34 (31–51)
T-BIL, μmol/L	0–21.0	10.9	11.4 (9.8–14.4)
Albumin, g/L	40.0–55.0	48.5	36.0 (32.5–40.0)
Creatinine, μmol/L	41.0–73.0	38	56 (42–69)
BUN, mmol/L	2.6–7.5	3.2	6.0 (4.4–7.2)
Amylase, U/L	35–135	76	62 (59–121)
>135 U/L	–	N	3 (25.0%)
Lipase, U/L	8–78	56	31 (24-48)
>78 U/L	–	N	3 (25.0%)
PT, s	11.5–14.5	12.5	12.5 (12.0–14.0)
APTT, s	29.0–42.0	37.5	35.6 (34.5–39.8)
INR	0.8–1.2	1.1	1.0 (0.9–1.0)
D-dimer, mg/L	0–1.5	0.2	0.1 (0.1–1.12)
PCT, ng/mL	0.02–0.05	0.04	0.32 (0.08–0.49)
CRP, mg/L	0–5.0	16	27.8 (18.8–86.0)
Ferritin, ng/mL	4.63–204	675	998 (701–1160)
Increased AMS/LPS after admission
Amylase, U/L	35–135	175	213 (186–277)
>135 U/L	–	Y	12 (100%)
Lipase, U/L	8–78	102	156 (104–228)
>78 U/L	–	Y	11 (91.7%)
Treatments
Oxygen support	–	N	12 (100%)
Mechanical ventilation	–	N	7 (58.3%)
Antiviral treatment	–	N	9 (75.0%)
Antimicrobial treatment	–	N	10 (83.3%)
Glucocorticoids	–	N	4 (33.3%)
ICU admission	–	N	6 (50.0%)
Outcome
Discharge	–	Y	7 (58.3%)
Dead	–	-	5 (41.7%)

ALT, alanine aminotransferase; AMS, amylase; APTT, activated partial thromboplastin time; ARDS, acute respiratory distress syndrome; AST, aspartate aminotransferase; BMI, body mass index; BUN, blood urea nitrogen, CHD, coronary heart disease; CRP, C-reactive protein, ICU, intensive care unit; INR, international standard ratio, LPS, lipase; NSAIDs, nonsteroidal anti-inflammatory drugs; PCT, procalcitonin, PT, prothrombin time; T-BIL, total bilirubin; WBC, white blood cells.

Discussion

In this study, we focused on the expression of ACE2 in the pancreas and the damage to the pancreas in a proportion of patients with SARS-CoV-2 infection. We found that ACE2 was expressed in the pancreas of normal people, and this expression was slightly higher in the pancreas than in the lungs, indicating that SARS-CoV-2 also might bind to ACE2 in the pancreas and cause pancreatic injury. Furthermore, single-cell RNA sequencing data indicated that ACE2 was expressed in both exocrine glands and islets of the pancreas.

In our study cohort, approximately 1% to 2% of nonsevere and 17% of severe patients with COVID-19 had pancreatic injury. In addition, it should be noted that some critically ill patients already had developed pancreatic injury before admission, and the possibility of drug-induced pancreatitis should be considered because of the history of taking nonsteroidal anti-inflammatory drugs and glucocorticoids in some patients. However, we should pay attention to the possibility of damage caused by SARS-CoV-2 based on the analysis of the expression of ACE2 in the pancreas and the high proportion of COVID-19 patients with pancreatic injury. Although these patients did not show signs of necrotizing pancreatitis, the consequences of pancreatic injury can be potentially serious, such as aggravating systemic inflammation, accelerating the occurrence of acute respiratory distress syndrome, and even developing into chronic pancreatitis, which may have a serious impact on the health and quality of life of patients. Yang et al , reported that patients infected with SARS-CoV suffered from hyperglycemia, which might be caused by SARS-CoV damaging the pancreatic islets through ACE2. Our results show that increased attention should be paid to the pancreas in patients with SARS-CoV-2 infection, especially in severe cases.